Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q2 sales rise 9% to $297.0 million; GAAP EPS $0.22 vs $0.17

Positive Impact 3 of 5 earnings Written later

Bio-Techne reported second-quarter fiscal 2025 results with net sales up 9% to $297.0 million and GAAP diluted EPS of $0.22, up from $0.17 a year earlier. Adjusted EPS rose to $0.42 from $0.40, while the adjusted operating margin held flat at 30.1%. For shareholders, quarterly revenue and profit both improved, though six-month GAAP diluted EPS was $0.42 versus $0.49 a year earlier.

Key points

  • Net sales rose 9% to $297.0 million for the quarter ended December 31, 2024.
  • GAAP diluted EPS was $0.22 versus $0.17; adjusted diluted EPS was $0.42 versus $0.40.
  • GAAP operating income increased 25% to $47.4 million; adjusted operating margin was flat at 30.1%.
  • Board appointed Dr. Amy Herr as an independent director effective February 1, 2025; a $0.08 per share quarterly dividend was also declared.

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECFeb 5, 2025, 6:30 AM ET
Accession number0001558370-25-000639

Items reported: 2.02 Results of Operations5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.